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Introduction: Antibiotic resistant strains of bacteria are an increasing problem in 
hospitals and in the community. This has resulted in bacterial infections such as 
impetigo becoming difficult to treat. Alternative treatment options are needed. 
Areas covered: In this paper a past study that assessed the health burden of 
scabies in North Queensland is described and from it the potential for 
formaldehyde as an alternative antimicrobial treatment is discussed. In doing so, 
antibiotic resistance, impetigo, permethrin and formaldehyde are introduced and 
the current understanding and limitations of the effects of formaldehyde on 
humans are outlined. The limited cases of formaldehyde resistance in bacteria is 
also discussed. 
Expert opinion: Formaldehyde is currently used as a preservative in cosmetics 
and medicinal creams due to its antibacterial activity. It therefore has the potential 
to be used as an alternative antibacterial treatment for infections with antibiotic 
resistant bacteria. The harmful side effects of airborne formaldehyde and exposure 
in allergic individuals have been extensively studied. Significantly less research 
has been conducted on formaldehyde skin contact in healthy individuals. If 
formaldehyde is safe for topical use in humans, it has the potential to assist with 
combating antibiotic resistance. 
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 The increasing incidence of antibiotic resistant strains of Staphylococcus aureus 
has increased the need for alternative treatment options. 
 Past work by Whitehall et al. [5] implicated treatment with a 5% permethrin 
cream as capable of curing infections with flucloxacillin resistant S. aureus. 
 Permethrin is a synthetic pyrethroid that is used in the treatment of scabies 
infections but has been found to have no antibacterial effect, implicating the 
formaldehyde preservative of the cream in Whitehall et al. [5] as being 
responsible for the observed antibacterial activity. 
 Formaldehyde is used in a wide variety of industries making it a ubiquitous 
indoor air pollutant that can cause a variety of harmful effects in humans 
including sensory irritation, carcinogenic effects in the respiratory system, 
allergic contact dermatitis and potentially increasing the rate of allergies and 
asthma in children. 
 Despite the wealth of research on the effects of airborne formaldehyde and 
dermally applied formaldehyde in allergic individuals, there is significantly less 
available information on the effect of dermally applied formaldehyde in non-
allergic individuals which is a major oversight in the literature. 
 If formaldehyde can be confirmed to be minimally harmful to humans as a 
topically applied cream, it represents an alternative to traditional antibiotics for 





The overuse and misuse of antibiotics has led to the development of antibiotic resistant 
strains of bacteria. These resistant strains have become a common problem in hospitals. 
Recently, in Australia, the incidence of community associated antibiotic resistance has 
been on the rise meaning that infections with resistant bacteria are no longer only 
occurring in hospitals, but also arising in the community [1]. One such bacterium that 
readily develops resistances to antibiotics is Staphylococcus aureus. S. aureus is a 
common skin commensal in humans but is also responsible for several infectious 
diseases, including skin and soft-tissue infections such as impetigo [2]. 
Impetigo and other infectious diseases generate significant disease burden and 
while current treatment options are mostly effective, more and more antibiotics are 
becoming unusable as more strains become resistant to them. It is therefore important 
that new treatment options that are effective against current resistant strains are 
identified, developed and used. It is also important that these new treatment options are 
capable of minimizing or preventing the ability for bacteria to develop resistance to 
them. This is why a substantial amount of research into new treatment options to 
combat resistant strains is currently being conducted. This is not limited to new 
antibiotics but also includes novel treatment options such as anti-virulence medication 
[3] and phage therapy [4]. Novel treatment options such as these are beneficial as it is 
less likely that bacteria will be able to develop resistance to them.  
A prior study by Whitehall et al. [5] assessed the health burden associated with 
scabies and pyoderma in children at Mt Isa Hospital. The bacteria present in the 
infections and the treatment methods were also identified. Group A streptococcus, S. 
aureus and Group C streptococcus were present in the infected children and these 
infections were treated with soap baths, flucloxacillin, a 5% permethrin cream and an 
 
 
adequate diet with iron supplementation as required. This was to cure both the scabies 
infections as well as the accompanying bacterial infections. What was interesting was 
that the patients all recovered despite most of the staphylococci strains being resistant to 
flucloxacillin. This implicates either the soap and water baths or the 5% permethrin 
cream as having a major benefit for treating antibiotic resistant bacterial infections. 
Permethrin is a synthetic pyrethroid used in the treatment of scabies infections 
[6]. It targets the voltage sensitive sodium channels of the mites, inactivating them 
causing prolonged depolarization, paralysis and death [7]. While the effect of 
permethrin on insects is well characterized, the literature does not contain any mention 
of any antibacterial properties of permethrin and so our lab worked to identify if it was 
capable of targeting bacteria. For this, strains of methicillin resistant S. aureus and 
methicillin sensitive S. aureus were grown in the presence of a range of concentrations 
of permethrin. The degree of growth inhibition was determined using viable counts. 
After conducting these experiments and finding no inhibition in bacterial growth, our 
attention turned to another component of the 5% permethrin cream - the 0.3% 
formaldehyde preservative. Combination inhibition experiments were then conducted 
using the same strains in the presence of 5% permethrin and 0.3% formaldehyde 
together as well as individually. In these combination experiments, 0.3% formaldehyde 
was capable of completely inhibiting bacterial growth regardless of the presence of 
permethrin. Furthermore, the inability of 5% permethrin to inhibit bacterial growth was 
reinforced. It is therefore most likely that the antibacterial activity observed in 
Whitehall et al. [5] was a result of the formaldehyde preservative and not the permethrin 
itself. 
If formaldehyde is effective in treating bacterial infections and safe for use in 
humans as a topical cream it represents a cheaper alternative to conventional antibiotic 
 
 
therapy and would be especially useful in cases where conventional antibiotics have 
failed, such as refractory impetigo. Formaldehyde could therefore help to reduce the 
burden associated with antibiotic resistant bacteria. However, there are risks associated 
with the use of formaldehyde and these would need to be considered and, in some cases, 
investigated further to get more information than is currently available in the literature 
before it can be used in this manner.  
2. Formaldehyde 
Formaldehyde is the simplest aldehyde and exists as a colorless gas with a strong odor 
at room temperature. It was first synthesized in 1855 and is used for a variety of roles. 
This includes in embalming, the manufacture of particle-board, plywood and other 
wooden furniture products and as a preservative in products such as cosmetics and 
medicinal creams [8]. When used as a preservative it is used as an aqueous solution of 
37%-50% formaldehyde called formalin [9]. Formaldehyde is used as a preservative 
due to its genotoxicity to bacteria and fungi. It is capable of binding to DNA and 
proteins to cause DNA-DNA cross-links, DNA-protein cross-links, irreversible 
formaldehyde adducts as well as other forms of DNA and protein damage [10,11]. It is 
effective against bacteria at very low concentrations with the MIC of formaldehyde 
against S. aureus being only 156 mg/L or 0.02% [12]. Formaldehyde has also been used 
to treat bacterial infections in the form of the antibiotic methenamine. Methenamine is 
an antibiotic that was used to treat urinary tract infections but has since become a 
“forgotten drug”. It exerts its antibacterial activity by releasing formaldehyde in acidic 
environments and is capable of bactericidal activity at concentrations greater than 25 
µg/ml [13].  
Due to its wide use and presence in nature, formaldehyde is a common airborne 
pollutant. As such it primarily enters the body through the respiratory system. It can 
 
 
also enter through ingestion and absorption through the skin. However, skin absorption 
of formaldehyde is considered to be poor [14,15]. Almost every body tissue has the 
ability to break down formaldehyde after absorption, converting it to the nontoxic 
formate [16]. 
The harmful effects of formaldehyde inhalation have been well reported in the 
literature leading to the development of guidelines to limit the allowed concentration of 
formaldehyde in the air. One such method to minimize the presence of airborne 
formaldehyde has been the use of formaldehyde releasing preservatives (such as 
Quaternium-15 and imidazolidinyl urea) rather than free formaldehyde. These 
formaldehyde releasing preservatives release formaldehyde slowly over time and this, in 
theory, allows for the concentration of formaldehyde present at any one time to remain 
low [17]. However, while much has been reported on the effects of airborne 
formaldehyde in humans, significantly less is available for dermal application of 
formaldehyde. Most of what is available is focused on the effects of formaldehyde in 
formaldehyde allergic individuals leading to allergic contact dermatitis with very little 
reported on the effect in non-allergic individuals. Furthermore, there are no in vivo 
human studies to identify the rate of formaldehyde absorption through the skin. This is 
despite the widespread use of formaldehyde in cosmetics and other products that 
regularly come into contact with the skin. 
2.1. Formaldehyde as an airborne pollutant 
Due to its generation by natural sources as well as its use in a variety of products, 
formaldehyde is a common indoor air pollutant. To minimize the potential for the 
adverse health effects associated with formaldehyde exposure, the World Health 
Organization (WHO) has developed an indoor air guideline for formaldehyde [18]. This 
was done as a result of the International Agency for Research on Cancer (IARC) 
 
 
classification of formaldehyde as a human carcinogen in 2004 as well as the other 
harmful effects airborne formaldehyde can exert on humans present in the literature. 
The WHO guideline is based on a literature review that determined the effects of 
different concentrations of airborne formaldehyde on humans. This ranged from mild 
sensory irritation to the carcinogenic effects of formaldehyde and the key studies are 
summarized below. 
Sensory irritation is generally defined as an unpleasant sensation in the eyes and 
airways, with eyes being more sensitive. Formaldehyde can cause sensory irritation and 
past studies have worked to identify the no observed effect level (NOEL) of 
formaldehyde. One such study was conducted on 21 individuals and consisted of a 
double blind random trial during which participants were exposed to various 
concentrations of formaldehyde [19]. Objective measurements of conjunctival redness, 
blinking frequency, nasal flow and resistance, pulmonary function, and reaction times 
were made before and after exposure to formaldehyde and used to evaluate the 
minimum concentrations required to exert irritation effects. This study found that eye 
irritation but not nasal irritation occurred at lower doses and the NOEL for 
formaldehyde exposure is 0.5 ppm for constant exposure and 0.3 ppm with peaks of 0.5 
ppm for short term exposure (Table 1). This value is consistent with a past review 
presented by Paustenbach et al. of 150 scientific articles [20]. Odor may also cause 
some minor irritation and past studies indicate that this may be detected at or below 
0.08 ppm [21,22].  
In addition to causing these mild irritating effects, formaldehyde has been 
identified as a potential carcinogen with sufficient evidence that it can cause upper 
airway cancers in animals and nasopharyngeal cancer in humans as classified by the 
IARC. A cohort study of 25,619 plant workers who regularly came into contact with 
 
 
formaldehyde was conducted that followed them from their year of employment 
(between 1934 and 1958) to December 31, 1994 [23]. The participants were divided 
into groups based on average formaldehyde exposure. An increased risk for death by 
nasopharyngeal cancer was supported for the highest concentrations of exposure (1 ppm 
to  4 ppm) (Table 1) and so for the purpose of airborne formaldehyde guidelines the 
WHO determined that formaldehyde exposure at or below 1 ppm does not induce excess 
nasopharyngeal cancer.  
The above literature examples as well as much more ultimately lead to the WHO 
guideline of indoor formaldehyde levels to remain below 0.08 ppm and to not exceed 
that threshold for more than 30 minutes at a time. This guideline was recommended as it 
is sufficient to prevent both sensory irritation in the general population as well as the 
long-term adverse effects such as cancer [18]. 
2.2. The effect of formaldehyde exposure in children 
As formaldehyde is near ubiquitous in the manufacture of common indoor products 
such as particle board, plywood and paneling, it represents a common indoor air 
pollutant that children are exposed to both in schools as well as at home. Children are 
more vulnerable to airborne toxic substances than adults as they have higher exposures 
per kilogram of body weight and because their respiratory system is not completely 
developed [24,25].  
Studies have been conducted to understand the harmful effects of prolonged 
airborne formaldehyde exposure on children. An Australian study measured indoor 
formaldehyde levels in children’s rooms and compared it with incidences of allergy and 
found that at higher formaldehyde exposure levels (still below local guidelines) children 
were at a higher risk of allergic sensitization [26]. A systematic review on the 
 
 
association between formaldehyde exposure and childhood asthma pooled results from 
seven studies and indicated that children exposed to formaldehyde had a 3.5 times 
higher chance of having asthma [27]. Some potential mechanisms to explain this are 
also highlighted in the review. The first explanation was formaldehyde as an irritant 
being able to provoke mucosal inflammation in airways and produce cytokine mediators 
associated with asthma. Another explanation is formaldehydes ability to associate with 
larger protein molecules creating new antigenic moieties leading to the formation of 
specific IgE antibodies that can then bind mast cells causing their degranulation, 
inducing asthmatic responses. This production of IgE is also supported by Wantke et al. 
[28]. A more recent meta-analysis also concluded that formaldehyde exposure levels are 
higher in children with asthma than those without [29].  
Recently however, Golden and Holm [30] raised concern that the associations 
seen between asthma and formaldehyde exposure may not be accurate as the chemical 
acrolein may be acting as an unrecognized confounder. Acrolein is capable of causing 
asthma and exists as an indoor air pollutant at levels higher than formaldehyde. Despite 
this, in prior studies looking at airborne contaminants and the development of asthma, 
acrolein was not considered. It may therefore have served as a confounder in these 
experiments and led to an overestimation of the association between formaldehyde and 
asthma.  
2.3. The effect of dermal application of formaldehyde 
Formaldehyde is a contact sensitizer that can cause allergic contact dermatitis in 
formaldehyde allergic individuals. In Europe the prevalence of formaldehyde allergy is 
2-3% whereas in the United States it is 8-9%. However, in the 1980s the prevalence of 
formaldehyde sensitization was much higher with sensitization occurring in 18% of 
individuals in Japan. After government regulations restricted the levels of formaldehyde 
 
 
permitted in underclothes this number dropped to 2.8%. This shows the importance of 
limiting prolonged formaldehyde exposure where possible [31]. It also shows the need 
for continued research into the effect of prolonged dermal contact with formaldehyde on 
the development of allergies and other harmful conditions. 
Formaldehyde caused allergic contact dermatitis presents as red spots, swelling, 
irritation, pain and a burning sensation (Table 1). It can also appear as lesions with the 
potential for widespread eruptions on formaldehyde exposed skin [16,31]. Current EU 
regulations allow for up to 0.2% or 2000 ppm of formaldehyde to be present in 
cosmetics and household products. If the amount of formaldehyde present exceeds 
0.05% (500 ppm) the label must have “contains formaldehyde” written on it [18]. 
However even formaldehyde at 500 ppm, can trigger allergic contact dermatitis in 
formaldehyde allergic individuals (Table 1) [32]. Formaldehyde allergies are diagnosed 
using a patch test. A 1% formaldehyde solution is used as standard but this test is often 
criticized for its high number of false positives (< 50% of positives are reproducible) 
[33] and false negatives [31]. 
While there is a substantial amount of research conducted on the effect of 
formaldehyde in allergic individuals, there is significantly less published about the 
effect of formaldehyde in healthy, non-allergic individuals. A majority of the available 
information was published in the late 80s. For example, two papers that deal with the 
topic of dermal contact of formaldehyde outside of allergic reactions are presented by 
Nair et al. [34] and Iversen [35] (Table 1). The former article details a trial study to test 
whether a 0.25% formalin spray was suitable for use in the treatment of burns in terms 
of the generation of eschar and the minimizing of bacterial infection. The spray was 
capable of assisting with the healing process by reducing the risk of infection. The latter 
article investigated whether topical applications of formaldehyde would lead to the 
 
 
generation of cancerous growths in mice. On its own, formaldehyde did not induce 
tumor growth but did decrease latency time in induced carcinogenesis. The observed 
result in Iversen [35] was then supported by another study by Iversen  [36] that repeated 
the same experiment but on SENCAR mice (which are more sensitive to chemical 
tumorigenesis) with similar results being observed (Table 1).  
A more recent study on the effects of dermal formaldehyde exposure was 
conducted by Saito et al. [37]. In this study the irritant effects of dermally applied 
formaldehyde to mice ears was investigated (Table 1). 2%, 5% and 10% solutions of 
formaldehyde caused ear swelling and the peak response increased with the 
concentration of formaldehyde. The expression of IL-4 was also increased. This study 
further confirmed the irritant activity of dermally applied formaldehyde but is limited in 
that the minimal concentration required for the induction of irritation was not identified.  
In addition to the limited study on the effect of dermally applied formaldehyde 
on human skin there is limited available literature on the rate of formaldehyde 
absorption through skin. No in vivo studies in humans have been conducted on the rate 
of absorption of formaldehyde through skin but some information is available using 
animals and excised human skin. One such animal study applied a cream containing 
radioactively tagged formaldehyde (0.1%) to the skin of rats [14]. At the end of the 
study no more than 5% of the applied formaldehyde was absorbed through the skin 
(Table 1). 
Another animal study tested formaldehyde absorption on rats, guinea-pigs and 
monkeys [38]. No accumulation of formaldehyde was found in any tissue with the 
majority of formaldehyde found in the air (Table 1). The skin of monkeys was less 
permeable to formaldehyde than the skin of rodents and a majority of formaldehyde was 
lost to evaporation. 
 
 
An experiment that used excised human skin tested absorption of both a 
formalin solution of 37% formaldehyde and 10% formaldehyde in phosphate buffer 
[15]. Skin absorption of formaldehyde occurred at 319 (for the formalin solution) and 
16.7 (for the phosphate buffer solution) micrograms per square centimeter per hour 
(Table 1).  
These results indicate that formaldehyde is poorly absorbed through undamaged 
skin. Furthermore, as mentioned above, the human body is capable of breaking down 
formaldehyde into the non-toxic formate. When taken together, harmful systemic 
effects of dermal formaldehyde exposure are unlikely. This is supported by the lack of 
formaldehyde accumulation in tissue as reported in Jeffcoat, Chasalow and Feldman 
[38]. However conducting in vivo studies on humans looking for the rate of absorption 
of formaldehyde through unbroken skin as well as any potential harmful effects from 
prolonged exposure would be reassuring given it is a common preservative in cosmetics 
and other dermally applied products. Such studies are however absent from the 
literature. 
2.4. Formaldehyde resistance in bacteria 
In addition to its wide use in manufacturing and as a preservative, formaldehyde is also 
an important cellular metabolite in the metabolism of methylated compounds in 
methylotrophic bacteria. It is generally produced by methanotrophic and methyltrophic 
bacteria during oxidation of hydrocarbons such as methane and methanol [10]. As a 
result, bacteria have developed methods to tolerate the toxic effects of formaldehyde. 
This has been primarily through the enzymatic breakdown of formaldehyde into less 
toxic products. One such method is found in Amycolatopsis methanolica and 
Mycobacterium gastri in the form of a formaldehyde dismutase that breaks 
formaldehyde down into formate and methanol. However, both species are still 
 
 
susceptible to formaldehyde at concentrations above 0.8mM [39].  
Formaldehyde resistance has been reported in Pseudomonas species and in the 
family Enterobacteriaceae. In Enterobacteriaceae, resistance developed as a result of 
plasmid acquisition while in Pseudomonas, resistance is chromosomally located. The 
resistances are due to the presence of formaldehyde dehydrogenase enzymes. 
Nicotinamide adenine dinucleotide (NAD) dependent formaldehyde dehydrogenases are 
found in methanol-utilizing methylotrophic bacteria like Pseudomonas methanica and 
some other formaldehyde-utilizing bacteria like Pseudomonas aeruginosa. As these 
species utilize formaldehyde it is essential that they are capable of surviving its 
presence. Strains of Escherichia coli resistant to formaldehyde have also been 
commonly found and it is accepted that resistance to formaldehyde is most often found 
in gram-negative bacteria [40]. Formaldehyde resistant strains of S. aureus have not 
been reported in the literature.   
3. Impetigo 
Impetigo is a skin infection that is most commonly found in children and can be caused 
by either S. aureus or Streptococcus pyogenes. Impetigo contributes to a high burden of 
disease in resource poor communities with an estimated global burden of 162 million 
children in low to low-middle income countries being affected by impetigo at any one 
time. In Australia alone, it is estimated that over 15,000 indigenous children suffer from 
impetigo at any one time [41]. The human skin barrier is usually capable of preventing 
bacteria from causing impetigo. However, if this protective layer is compromised, by 
conditions such as chickenpox and scabies or through damage caused by scratching or 
surgery, bacteria can invade and colonize, leading to the development of impetigo. 
Impetigo presents in three main forms and is primarily caused by S. aureus. The 
first, called non-bullous impetigo presents as a maculopapular lesion that becomes a 
 
 
thin-walled vesicle. The vesicle ruptures and dries as a yellowish crust. The second 
presentation, called bullous impetigo presents as small vesicles at first that then become 
localized blisters. These blisters do not rupture as easily as the vesicles in non-bullous 
impetigo. The final presentation of impetigo is called ecthyma. Ecthyma extends further 
into the dermis layer than the other two forms, and is characterized by vesicles that 
rupture producing circular ulcers with black-brown crusts. All three forms can also be 
caused by S. pyogenes but this is less common [42].  
Impetigo is usually treated with topical antibiotic creams but if the infection is 
more severe, or is a case of refractory impetigo, an oral antibiotic will be administered 
instead. The first choice creams for topical treatment of impetigo are fusidic acid and 
mupirocin. The use of a topical cream is preferred to an oral antibiotic as it results in 
fewer side effects [42]. Strains of S. aureus resistant to two common antibiotics used for 
the treatment of impetigo, fusidic acid [43] and mupirocin, [44] have been reported. 
This growing resistance has led to the use of retapamulin as an alternative treatment 
option [45].  
4. Conclusion 
Currently many clinically important strains of bacteria are resistant to antibiotics with 
some even resistant to what were considered to be last resort antibiotics. If something is 
not done, we may enter the post antibiotic era where infections that were once easy to 
treat become untreatable. This would increase both the number of deaths from bacterial 
infections as well as the burden of cost associated with extended hospital stays. 
Formaldehyde has been implicated in a prior study as being able to decrease infection 
by antibiotic resistant bacteria when applied as a cream. Furthermore, it is already used 
in cosmetics and medicinal creams as a preservative. It is therefore capable of killing 
bacteria and is safe to be used in humans at controlled concentrations. The available 
 
 
literature indicates that formaldehyde is poorly absorbed through the skin and it is 
difficult for bacteria to develop resistance to it. With further research into its prolonged 
effect on humans after topical application, formaldehyde may represent an antimicrobial 
capable of alleviating the burden associated with antibiotic resistance and help to treat 
infections that may otherwise be untreatable.  
5. Expert opinion 
Treatment of bacterial infections has in the past been done irresponsibly. This is both in 
terms of the prescription of antibiotics when unnecessary and the prescription of broad 
spectrum antibiotics when a narrower spectrum would have sufficed. As a result of this 
overuse and misuse of antibiotics, antibiotic resistant strains of bacteria have become a 
major threat both in hospitals and in the wider community. New treatment options are 
needed as more and more antibiotics become ineffective. However, increased antibiotic 
development will not solve the problem of resistance as new resistances can and will 
always develop. Novel methods that are harder or even impossible for bacteria to 
develop resistance against are needed along with responsible treatment practices. 
Formaldehyde with its genotoxic effects against bacteria is already used as a 
preservative in cosmetics and medicinal creams and as the active ingredient in the 
antibiotic methenanime. It is also very difficult for gram positive bacteria to develop 
resistance to formaldehyde. Formaldehyde therefore represents a promising potential 
alternative treatment option for infections with antibiotic resistant bacteria. However, in 
order for formaldehyde to be used as an antibacterial, its harmful effects on humans 
would need to be taken into account. This is however made difficult by the absence of 
key information in the literature. 
Formaldehyde has been extensively studied in terms of the risks it poses as an 
airborne pollutant. Its effect on allergic individuals after skin contact has also been 
 
 
studied and reported in the literature. However, the potential negative effects of 
dermally applied formaldehyde in non-allergic individuals has not been studied nearly 
as rigorously. Nor has the rate of skin absorption in humans with no in vivo human 
studies conducted. What little information is available is over 30 years old and for a 
chemical as ubiquitous as formaldehyde this is concerning. If there is so much 
regulation and research done on the harmful effects of airborne formaldehyde, then why 
is there not nearly as much available for dermally applied formaldehyde? Either it is not 
as dangerous in this form or it is an oversight. Either way it represents a worrying 
absence in the literature and a potential avenue for future research. 
The currently available literature, though old, does indicate that dermally 
applied formaldehyde is poorly absorbed by undamaged skin and that what little is 
absorbed is rapidly detoxified with little to no spread to organs. When this is combined 
with the continued use of low concentrations of formaldehyde in dermally applied 
products, it would appear that minimal dermal application of formaldehyde is safe for 
use in non-allergic humans. Before formaldehyde can be recommended for use as a 
novel antibacterial for treatment of infections with antibiotic resistant bacteria however, 
there is a need for more in depth research into the effects of dermally applied 
formaldehyde. If, after further research is conducted, the results of past studies are 
confirmed along with a confirmation that the application of a cream containing 
formaldehyde does not cause harm to the patient, does not increase their chance of 
developing cancer, does not increase airborne formaldehyde concentration above 
hazardous levels, is not absorbed at toxic levels, does not contribute to the development 
of asthma and does not facilitate the development of a formaldehyde allergy, it could be 
used to treat infectious diseases. For example, it could be used in situations where 
traditional antibiotics have failed (such as refractory impetigo) as a new treatment 
 
 
option. If done so it will be able to treat bacterial infections that have become 
untreatable as a result of the rise of antibiotic resistance. Though limited, the available 
literature does indicate that formaldehyde would be suitable for use in this manner. 
Formaldehyde also opens itself to help reduce the cost of treatment for some 
diseases. For example, in scabies infections an insecticide is needed to treat the scabies 
mite infection and an antibiotic is needed to treat the secondary bacterial infections. If 
formaldehyde is suitable for the treatment of bacterial infections in humans, rather than 
treating scabies and the accompanying secondary bacterial infections with two separate 
medicines, a single insecticide cream with a formaldehyde preservative would suffice. 
Formaldehyde has the potential to help alleviate the problems associated with 
antibiotic resistance but without further research into the safety of formaldehyde use in 
humans, it cannot be recommended for use in this way. Therefore, it is essential that in 
the near future research is conducted on the effects that dermal formaldehyde 
application exerts when applied on humans. 
As infections with antibiotic resistant strains of S. aureus have reached epidemic 
levels all over the world, new antibiotics and new novel treatment options are needed 
[46]. Formaldehyde represents just one potential weapon to fight back against antibiotic 
resistance. If these new treatment options are found and used responsibly the threat 
antibiotic resistance poses can begin to be reversed. However, if effective treatments are 
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